BioSpace News Archive

CEOs at Sana Biotechnology and BioLife Solutions explain how being based in the BioForest region helped them be voted one of BioSpace’s best places to work in 2023.

If you’re considering working from home in the life science industry, you might want to apply for remote clinical jobs. Continue reading to discover seven examples of remote clinical jobs and how to get them.

AstraZeneca dosed the first patient in a Phase II portion of an ongoing trial assessing a PD-1/TIGIT bispecific antibody, triggering a $7.5 million milestone payment to partner, Compugen.

Huntington’s disease might just top the list of intractable neurodegenerative diseases. BioSpace spoke with the field’s foremost experts about the challenges and how to overcome them.

Tricida, Inc. is reducing its headcount by around 57% to improve its financial standing after its lead candidate failed in a Phase III trial, the company revealed in its third-quarter financial results.

In the acquisition, announced Wednesday, Kriya picks up two gene therapy programs focused on epilepsy and trigeminal neuralgia. Financial terms of the deal were not disclosed.

Ardelyx has moved one step closer to the possible approval of its experimental chronic kidney disease drug tenapanor following a favorable 9-4 vote from an FDA advisory committee.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, CEO, and Michael Holder, CFO, on November 23, 2022 at 4:00pm (PST) / November 24, 2022 at 11:00am (AEDT).

HIROTSU BIO SCIENCE INC. is pleased to announce the commercialization of “N-NOSE plus Pancreas,” the first next-generation “cancer type specific test” for the “N-NOSE®".

Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, reported unaudited financial results for the first nine months of 2022 and provided a summary of recent corporate highlights.